Aurobindo Pharma announced that it has receives first product approval from Swissmedic, Government of Switzerland for license Finasteride APL Tablets 5mg.
Finasteride APL Tablets 5mg is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with enlarged prostrate.
The company is a fast-track integrated pharmaceutical company headquartered in Hyderabad, India, producing and marketing active pharmaceutical ingredients (bulk actives), intermediates and specialty generic formulations.
Shares of the company gained Rs 0.5, or 0.26%, to trade at Rs 190.50. The total volume of shares traded was 1,366.00 at the BSE (10.15 a.m., Wednesday).